Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

STRATEC SE Interim / Quarterly Report 2026

May 11, 2026

416_ir_2026-05-10_d1bd491c-39c9-409e-bc95-2731e50dbec5.pdf

Interim / Quarterly Report

Open in viewer

Opens in your device viewer

stratec

img-0.jpeg

STRUCTURED FOR PROGRESS

QUARTERLY

STATEMENT

Q1|2026

January 1 to March 31, 2026


STRATEC QUARTERLY STATEMENT Q1|2026

STRATEC POSTS RESULTS FOR THE FIRST QUARTER OF 2026

  • Significant rise in free cash flow to € 18.6 million in Q1/2026 (Q1/2025: € -8.3 million)
  • Consolidated sales and key profitability figures decreased as previously communicated, but remain within the intra-year planning corridor; ongoing strong momentum in the Systems business
  • Well-filled development pipeline and progress in transferring projects to serial production
  • 2026 guidance confirmed: Constant-currency sales expected to show growth in medium to high single-digit percentage range with adjusted EBIT margin at previous year's level (10.0%)

Key figures¹

€ 000s Q1/2026 Q1/2025 Change
Sales 53,426 60,363 -11.5%
(CC: -8.8%)
Adjusted EBITDA 4,691 9,305 -49.6%
Adjusted EBITDA margin (%) 8.8 15.4 -660 bps
Adjusted EBIT 691 5,363 -87.1%
Adjusted EBIT margin (%) 1.3 8.9 -760 bps
Adjusted consolidated net income -1,110 3,155 n/a
Adjusted earnings per share (€) -0.09 0.26 n/a
Free cash flow 18,597 -8,329 n/a

bps = basis points
cc = constant currency

¹ To facilitate comparison, figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganization expenses).


BUSINESS PERFORMANCE

The consolidated sales of the STRATEC Group amounted to € 53.4 million in the first quarter of 2026, compared with € 60.4 million in the previous year's quarter. This corresponds to a constant-currency sales decline of 8.8% (nominal: -11.5%) and is thus consistent with the expectations underpinning the company's intra-year planning. The notably more dynamic performance recently seen in the Systems business continued, with double-digit growth rates in the first quarter of 2026. By contrast, the Service Parts and Consumables business posted a reduction in sales due to logistics optimization measures at customers. Sales from Development and Services also decreased as, in line with expectations, it was not possible to repeat the high volume achieved in the previous year.

Due to negative scale effects and significant sales and product mix effects, particularly due to the lower share of high-margin Service Parts and Consumables sales, adjusted EBIT fell from € 5.4 million in the previous year's period to € 0.7 million in the first quarter of 2026. The adjusted EBIT margin therefore stood at 1.3% and, consistent with the company's intra-year planning, fell significantly short of the previous year's figure of 8.9%.

The reduction in operating profitability also led adjusted consolidated net income to decrease from € 3.2 million in the previous year to € -1.1 million. Adjusted earnings per share (diluted) for the first quarter of 2026 therefore stood at € -0.09, as against € 0.26 in the previous year.

Free cash flow improved significantly, rising from € -8.3 million in the previous year's quarter to € 18.6 million in the first quarter of 2026. This positive cash flow performance was driven by the strong momentum in Systems sales that had already emerged toward the end of the 2025 financial year. Given what remains a highly pronounced degree of seasonality, this led the elevated volume of trade receivables reported at the end of the year to decrease in Q1 2026.

Reconciliation of adjusted EBITDA, EBIT, and consolidated net income

To facilitate comparison, the earnings figures have been adjusted to exclude amortization resulting from purchase price allocations in the context of acquisitions and other non-recurring items (including one-off advisory expenses, fees, and reorganization expenses). A reconciliation of the adjusted results with the unadjusted key earnings figures is presented below:

Reconciliation of adjusted EBITDA (€ 000s)
Q1/2026 Q1/2025
Adjusted EBITDA 4,691 9,305
Adjustments:
Other^{1} -239 -1,369
EBITDA 4,452 7,936

1 Including one-off advisory expenses, fees, and reorganization expenses

Reconciliation of adjusted EBIT (€ 000s)
Q1/2026 Q1/2025
Adjusted EBIT 691 5,363
Adjustments:
PPA amortization -556 -924
Other^{1} -239 -1,369
EBIT -104 3,070

1 Including one-off advisory expenses, fees, and reorganization expenses

Reconciliation of adjusted consolidated net income (€ 000s)
Q1/2026 Q1/2025
Adjusted consolidated net income -1,110 3,155
Adjusted earnings per share in € (basic) -0.09 0.26
Adjustments:
PPA amortization -556 -924
Other^{1} -239 -1,369
Taxes 192 584
Consolidated net income -1,713 1,446
Earnings per share in € (basic) -0.14 0.12

1 Including one-off advisory expenses, fees, and reorganization expenses


STRATEC QUARTERLY STATEMENT Q1|2026

2026 FINANCIAL GUIDANCE

Overall, the first-quarter sales and earnings performance is consistent with the assumptions made in the company's intra-year planning for the 2026 financial guidance. As a result, and based on current orders and order forecasts received from customers, STRATEC's Board of Management can confirm the guidance provided for the 2026 financial year. STRATEC expects to generate year-on-year constant-currency consolidated sales growth in a medium to high single-digit percentage range in the 2026 financial year. The resultant benefits of scale are expected to be partly to fully offset by rising input costs due not least to adverse geopolitical factors. Accordingly, the adjusted EBIT margin for 2026 is expected to be around to the previous year's level (2025: 10.0%).

Furthermore, investments in property, plant and equipment and in intangible assets corresponding to a total of 6.5% to 8.5% of sales are still budgeted for the 2026 financial year (2025: 6.5%).


5

PROJECTS AND OTHER DEVELOPMENTS

STRATEC has a well-filled development pipeline and, together with its partners, pressed further ahead with numerous developments and projects once again in the first quarter of 2026. Two system developments, for example, are currently being transferred to serial production and therefore approaching market launch by the respective customers. STRATEC is also holding numerous promising negotiations for additional collaborations with existing and new partners.

DEVELOPMENT IN PERSONNEL

Including personnel hired from employment agencies and trainees, the STRATEC Group had a total of 1,395 employees at the end of the first quarter of 2026, compared with 1,443 in the previous year's period. This reduction by 3.3% is aligned to the business performance and also reflects the consistent implementation of measures in the Operational Excellence program.


STRATEC QUARTERLY STATEMENT Q1|2026

CONSOLIDATED BALANCE SHEET

as of March 31, 2026

Assets

€ 000s 03.31.2026 12.31.2025
Non-current assets
Goodwill 50,275 49,853
Other intangible assets 58,427 58,157
Right-of-use assets 11,366 12,192
Property, plant and equipment 63,355 64,452
Non-current financial assets 4,080 4,085
Non-current other receivables and assets 294 294
Non-current contract assets 21,794 21,390
Deferred taxes 2,430 2,162
212,021 212,585
Current assets
Inventories 114,474 113,185
Trade receivables 43,437 56,933
Current financial assets 1,189 1,345
Current other receivables and assets 6,091 6,247
Current contract assets 5,865 8,228
Income tax receivables 2,162 4,407
Cash 23,740 23,056
196,958 213,401
Total assets 408,979 425,986

Shareholders' equity and debt

€ 000s 03.31.2026 12.31.2025
Shareholders' equity
Share capital 12,158 12,158
Capital reserve 37,599 37,498
Revenue reserves 188,018 189,732
Treasury stock -35 -35
Other equity -946 -2,033
236,794 237,320
Non-current debt
Non-current financial liabilities 102,107 110,653
Other liabilities 1,133 1,105
Non-current contract liabilities 2,350 2,039
Provisions for pensions 4,132 4,158
Provisions 116 116
Deferred taxes 16,885 16,854
126,723 134,925
Current debt
Current financial liabilities 14,868 24,862
Trade payables 13,523 12,635
Current other liabilities 10,823 9,757
Current contract liabilities 3,285 4,305
Provisions 463 461
Income tax liabilities 2,500 1,721
45,462 53,741
Total shareholders' equity and debt 408,979 425,986

7


STRATEC QUARTERLY STATEMENT Q1|2026

CONSOLIDATED STATEMENT OF COMPREHENSIVE INCOME

for the period from January 1 to March 31, 2026

€ 000s 01.01. – 03.31.2026 01.01. – 03.31.2025
Sales 53,426 60,363
Cost of sales -43,225 -44,325
Gross profit 10,201 16,038
Research and development expenses -1,718 -2,242
Sales-related expenses -3,261 -3,355
General administration expenses -5,561 -6,891
Income / Expenses from impairment of financial assets and contract assets -103 -230
Other operating expenses -1,212 -1,374
Other operating income 1,550 1,124
Earnings before interest and taxes (EBIT) -104 3,070
Financial income 34 65
Financial expenses -1,021 -1,118
Other financial result -65 -61
Net financial result -1,052 -1,114
Earnings before taxes (EBT) -1,156 1,956
Taxes on income -557 -510
Consolidated net income -1,713 1,446
Items that may be subsequently reclassified to profit or loss:
Currency translation differences from translation of foreign operations 1,087 930
Other comprehensive income (OCI) 1,087 930
Comprehensive income -626 2,376
Basic earnings per share in € -0.14 0.12
No. of shares used as basis (undiluted) 12,155,942 12,155,942
Diluted earnings per share in € -0.14 0.12
No. of shares used as basis (diluted) 12,155,942 12,155,942

CONSOLIDATED STATEMENT OF CASH FLOWS

for the period from January 1 to March 31, 2026

€ 000s 01.01. – 03.31.2026 01.01. – 03.31.2025
I. Operations
Consolidated net income (after taxes) -1,713 1,446
Depreciation 4,556 4,866
Current income tax expenses 787 581
Income taxes paid less income taxes received 2,233 -4,873
Financial income -34 -65
Financial expenses 1,021 1,118
Interest paid -1,683 -1,085
Interest received 33 88
Other non-cash expenses 824 1,797
Other non-cash income -826 -1,082
Change in net pension provisions through profit or loss -49 -50
Change in deferred taxes through profit or loss -230 -71
Profit (-)/loss (+) on disposals of non-current assets -94 0
Increase (-)/decrease (+) in inventories, trade receivables and other assets 15,298 -839
Increase (+)/decrease (-) in trade payables and other liabilities 1,370 -4,984
Cash flow from operating activities 21,493 -3,153
II. Investments
Outgoing payments for investments in non-current assets
• Intangible assets -1,344 -2,341
• Property, plant and equipment -1,551 -2,835
Cash flow from investing activities -2,896 -5,176
III. Financing
Incoming funds from taking up of financial liabilities 0 1,000
Outgoing payments for repayment of financial liabilities -17,177 -22,584
Outgoing payments for repayment of lease liabilities -894 -824
Cash flow from financing activities -18,071 -22,408
IV. Cash-effective change in cash (net balance of I–III) 526 -30,737
Cash at start of period 23,056 47,164
Impact of exchange rate movements 158 -313
Cash at end of period 23,740 16,114

9


STRATEC QUARTERLY STATEMENT Q1|2026

FINANCIAL CALENDAR

| 05
05.11.2026
Quarterly Statement
Q1|2026 | 06
06.23.2026
Annual
General Meeting | 08
08.14.2026
Half-year Financial
Report H1|2026 | 11
11.12.2026
Quarterly Statement
9M|2026 | 11
11.24.2026
German Equity Forum
(Analyst Conference) |
| --- | --- | --- | --- | --- | --- | --- | --- |

Subject to amendment.

Quarterly statements and half-year financial reports are neither audited nor subject to an audit review by the group auditor.

ABOUT STRATEC

STRATEC SE (www.stratec.com) designs and manufactures fully automated analyzer systems for its partners in the fields of clinical diagnostics and life sciences. Furthermore, the company offers complex consumables for diagnostic and medical applications. For its analyzer systems and consumables, STRATEC covers the entire value chain – from development to design and production through to quality assurance.

The partners market the systems, software and consumables, in general together with their own reagents, as system solutions to laboratories, blood banks and research institutes around the world. STRATEC develops its products on the basis of patented technologies.

Shares in the company (ISIN: DE000STRA555) are traded in the Prime Standard segment of the Frankfurt Stock Exchange.

IMPRINT AND CONTACT

Published by

STRATEC SE

Gewerbestr. 37

75217 Birkenfeld

Germany

Phone: +49 7082 7916-0

[email protected]

www.stratec.com

Head of Investor Relations, Sustainability & Corporate Communications

Jan Keppeler

Phone: +49 7082 7916-6515

[email protected]

Notice

Forward-looking statements involve risks: This quarterly statement contains various statements concerning the future performance of STRATEC. These statements are based on both assumptions and estimates. Although we are convinced that these forward-looking statements are realistic, we can provide no guarantee of this. This is because our assumptions involve risks and uncertainties which could result in a substantial divergence between actual results and those expected. It is not planned to update these forward-looking statements.

This quarterly statement contains various disclosures that from an economic point of view are not required by the relevant accounting standards. These disclosures should be regarded as a supplement, rather than a substitute for the IFRS disclosures.

Apparent discrepancies may arise throughout this quarterly statement on account of mathematical rounding up or down in the course of addition.

This quarterly statement is available in both German and English. Both versions can be downloaded from the company's website at www.stratec.com. In the event of any discrepancies between the two, the German report is the definitive version.